 Home > Active Ingredient News > Immunology News > J Dermatolog Treat: Analysis of Disease Activity and Treatment Effects Using Patient-Level Psoriasis Area and Severity Index Scores in Phase 3 Clinical Trials

J Dermatolog Treat: Analysis of Disease Activity and Treatment Effects Using Patient-Level Psoriasis Area and Severity Index Scores in Phase 3 Clinical Trials

 Last Update: 2022-05-14
 Source: Internet
 Author: User

Tags

cilostazol 100 mg

melt flow index

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Recently, several new drugs have been approved to treat moderate to severe plaque psoriasis

This post hoc analysis used tiralizumab 100 mg (N = 616) or placebo (N = 309) pooled patient-level data after treatment

RESULTS: The median baseline Psoriasis Area and Severity Index (PASI) was 17.

Taken together, the findings of this study suggest that the PASI score is more reliable for estimating disease activity than the percentage improvement in PASI; this may be partly responsible for the differences in efficacy between clinical trials and practice

Original source:

KB Gordon, et al.

leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Melatonine 99

CAS No.: 73-31-4

pharmaceutical grade

$100/KG FOB

China Largest Manufacturer Supply High Purity ISOPRINOSINE CAS 36703-88-5

CAS No.: 36703-88-5

Pharmacy Grade

$3-3.5/KG FOB

API Rapamycin Powder 53123-88-9 99% Sirolimus powder

CAS No.: 53123-88-9

Pharmacy Grade

$2-2.5/KG FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.